Postmenopausal: Clinical Trials

5 trials for Postmenopausal, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

5 completed. 5 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 15Completed 5

Follow Postmenopausal: new trials by email Literature Review of Postmenopausal trials Research Report on Postmenopausal

Trials (filtered) newest first · largest first

All 5 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Study to Investigate Safety, Tolerability and Pharmacokinetics of LAE102 in Postmenopausal Women
LAE102 SC, Placebo SC, LAE102 IV - Postmenopausal, Healthy Adult Female Participants
Phase 1CompletedLaekna Limited322025-04-222025-11-17
Everolimus, Letrozole and Trastuzumab in HR- and HER2/Neu-positive Patients
Everolimus, Laboratory Biomarker Analysis, Letrozole - Advanced Malignant Solid Neoplasm, Estrogen Receptor Positive
Phase 1CompletedM.D. Anderson Cancer Center372014-07-172020-12-19
AZD1981 Bioavailability Study of Intravenous (IV) and Oral Formulations
AZD1981 - Healthy, Postmenopausal
Phase 1CompletedAstraZeneca142009-06-012009-07-30
Food Effects on the Relative Bioavailability of Different Dosages of Risedronate
risedronate - Postmenopausal, Non-lactating
Phase 1CompletedWarner Chilcott942008-07-012011-10-12
A Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Romosozumab (AMG 785)
Romosozumab, Placebo - Postmenopausal, Osteopenia
Phase 1CompletedAmgen482007-11-142023-08-30

Narrower conditions

Bone Diseases, Metabolic (1)  ·  Breast Neoplasms (1)

Broader conditions

Bone Diseases (1)  ·  Breast Diseases (1)  ·  Metabolic Diseases (1)  ·  Musculoskeletal Diseases (1)  ·  Neoplasms (1)  ·  Neoplasms by Site (1)  ·  Nutritional and Metabolic Diseases (1)  ·  Skin Diseases (1)  ·  Skin and Connective Tissue Diseases (1)

Interventions

AZD1981 (1)  ·  Everolimus (1)  ·  Letrozole (1)  ·  Ogivri (1)  ·  PF-05280014 (1)  ·  Risedronic Acid (1)  ·  Trastuzumab (1)  ·  romosozumab (1)  ·  trastuzumab biosimilar HLX02 (1)

Sponsors

Amgen (1)  ·  AstraZeneca (1)  ·  Laekna Limited (1)  ·  M.D. Anderson Cancer Center (1)  ·  Warner Chilcott (1)

Countries

United States (3)  ·  Sweden (1)

Top investigators

Dr. Hugh Coleman, MD (1)  ·  Elisabeth Eden (1)  ·  Eva Pettersson (1)  ·  Filip Janku (1)

Results publications

PMID 33115815

NIH funding

P30CA016672 (1)